GeNeuro’s Pipeline Overview

GeNeuro’s approach involves targeting and neutralizing pathogenic proteins encoded by human endogenous retroviruses (HERV) which could play a causal role in the development of poorly understood diseases, notably autoimmune disorders.

In multiple sclerosis, GeNeuro is testing a therapeutic antibody against the envelope protein of the endogenous retrovirus MSRV, which may feed the inflammation and neurodegeneration characteristic of multiple sclerosis. GeNeuro believes the upstream neutralization of this protein is the first approach against a causative factor of the disease.

GeNeuro capitalizes on the potential of its technology by developing an exclusive therapeutic platform focused on diseases potentially induced by human endogenous retroviruses. It has started in April 2017 a Phase IIa on 60 patients affected by type 1 diabetes, a disease where over 50% of the patients express the pathogenic MSRV protein in their pancreas, where it could play a causal role. Other indications targeted by GeNeuro include CIDP (chronic inflammatory demyelinating polyneuropathy), an orphan neurological disease where a Phase IIa proof-of-concept is planned for 4Q2017.

To capture the full therapeutic potential of its approach against pathogenic HERV proteins, GeNeuro is developing other approaches, currently at preclinical stage, against inflammatory psychosis, as well as against amyotrophic lateral sclerosis in a research partnership with the NIH.

GeNeuro may also develop diagnostic tests to test for pathogenic HERV proteins in patients. These tests would detect the presence of the antigen in the blood of patients and could be used as companion diagnostics in a personalized medicine approach.